- EU law requires that for centrally authorised medicinal products, the marketing authorisation holders are established in the EU (or EEA). That means a pharmaceutical company will need a registered and licenced office or facility with licence in the EU/EEA.
- Some activities like, for example, batch release and pharmacovigilance activities must be performed in the EU (or EEA). Therefore, QP and QPPV must be located in the EU/EEA.
- Possible changes to the terms of the marketing authorisation “in order to ensure its continuous validity and exploitation” should be considered.
- Assess your regulatory impact and develop your Brexit transition strategy
- Manage MAH transfers and other necessary variations
- RMS Transfers
- Act as your QPPV
- Batch update all your records with the new QPPV and PSFM information in the Article 57 database
- Hold your pharmacovigilance system master file at our location
- Re-establish your SME status